Cancer Therapy Advisor is looking forward to delivering news coverage of the 2018 San Antonio Breast Cancer Symposium (SABCS 2018), live from the Henry B. Gonzalez Convention Center in Texas, starting December 4 through 8.

Look for these reports and more from Cancer Therapy Advisor’s team of reporters

Landscape of the Breast Tumor Microenvironment at Single-Cell Resolution

Continue Reading

Findings that reveal new biomarkers and opportunities for stromal- and immune-based therapy for patients with breast cancer.

Efficacy Results from CIBOMA/2004-01_GEICAM/2003-11 Study

A randomized phase 3 trial that assesses adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer.

Phase 3 study of Trastuzumab Emtansine (T-DM1) Compared With Trastuzumab as Adjuvant Therapy

Primary results from KATHERINE, a study of patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab.

Pathological Complete Response After Neoadjuvant Chemotherapy and Affect on Breast Cancer Recurrence and Mortality

A study stratified by breast cancer subtypes and adjuvant chemotherapy usage that includes individual patient-level meta-analyses of over 27,000 women.

Results of the PALLET trial

A neoadjuvant study to compare the clinical and antiproliferative effects of letrozole with and without palbociclib in patients with breast cancer.

Results of the N-SAS BC 05 Trial: Arimidex Extended Adjuvant Randomized Study (AERAS)

A prospective randomized multicenter open-label phase 3 trial of extending aromatase-inhibitor adjuvant therapy to 10 years.


Daily coverage on the website ( will be posted throughout the meeting as research is presented. Be sure to check back for the latest news coming out of SABCS 2018!